Welcome to our dedicated page for Transcode Therapeutics news (Ticker: RNAZ), a resource for investors and traders seeking the latest updates and insights on Transcode Therapeutics stock.
TransCode Therapeutics, Inc. (NASDAQ: RNAZ) generates a steady flow of news as a clinical-stage oncology company advancing RNA-targeted therapeutics for cancer. This news page aggregates press releases and third-party coverage related to TransCode’s development programs, corporate actions, and scientific collaborations, giving readers a centralized view of how the company’s RNA oncology strategy is progressing.
Much of the company’s news focuses on its lead candidate, TTX-MC138, an RNA-based therapeutic designed to inhibit microRNA-10b (miR-10b), which TransCode identifies as a key factor in metastatic cancer. Updates include milestones from its Phase 0 and Phase 1a clinical trials in metastatic solid tumors, reports on safety and pharmacodynamic data, and announcements about advancing TTX-MC138 into Phase 2a studies across selected metastatic indications and minimal residual disease settings.
Readers can also follow news about preclinical research using the TTX platform, such as studies in glioblastoma models demonstrating delivery of TTX-MC138 to brain tumors, target engagement, and extended survival in murine models. These items highlight how TransCode’s nanoparticle platform is being evaluated for systemic delivery of RNA therapeutics to challenging tumor sites.
Beyond clinical and preclinical data, TransCode’s news includes corporate and strategic developments, such as the acquisition of Polynoma and the addition of seviprotimut-L, a polyvalent shed antigen vaccine for stage IIB and IIC melanoma, to its pipeline. Filings and releases also cover financing transactions with affiliates of CK Life Sciences, reverse stock split decisions related to Nasdaq listing requirements, and governance updates including board and executive appointments.
For investors, researchers, and clinicians, following RNAZ news offers insight into TransCode’s progress in metastatic disease, its expanding immuno-oncology and RNA pipeline, and the regulatory and capital markets events that shape its development path. Bookmark this page to review new trial readouts, platform data, and transaction announcements as they are released.
TransCode Therapeutics (NASDAQ: RNAZ) has announced successful completion of initial dosing in Cohort 4 of its Phase 1a clinical trial for TTX-MC138. Key highlights include:
- 15 patients treated across 4 dose levels (0.8 mg/kg to 4.8 mg/kg)
- No significant safety or dose-limiting toxicities reported
- 10 patients remain on study with stable disease
- Two patients received 7 doses over ~7 months showing stable disease
- PK/PD data shows predictable dose-response relationship
- Evidence of miR-10b target engagement at 24 hours post-infusion in Cohorts 1 and 2
- Safety Review Committee approved expanded enrollment in Cohort 3
The positive results support advancement to the Phase 1b dose expansion portion of the trial.
TransCode Therapeutics (NASDAQ: RNAZ) has announced a 1-for-28 reverse stock split effective May 15, 2025, at 12:01 a.m. EST. The split aims to increase the per-share trading price to meet Nasdaq's minimum bid price requirement for continued listing. The reverse split will reduce outstanding common shares from 23,341,336 to approximately 833,620. The company's stock will continue trading under the symbol "RNAZ" on the Nasdaq Capital Market.
Stockholders will receive one new share for every 28 current shares, with fractional shares rounded up to the nearest whole number. Proportional adjustments will be made to outstanding stock options, warrants, and shares under stock incentive plans. Vstock Transfer LLC will serve as the exchange agent, and the company's CUSIP number will change to 89357L 501.
TransCode Therapeutics (NASDAQ: RNAZ) has announced a 1-for-28 reverse stock split approved by its Board of Directors and stockholders on May 2, 2025. The split aims to increase the company's per share trading price to meet Nasdaq's minimum bid price requirements for continued listing. The reverse split will reduce outstanding common shares from 23,341,336 to approximately 833,620.
The conversion will automatically convert 28 current shares into one new share, with fractional shares rounded up to the nearest whole number. Proportional adjustments will be made to outstanding stock options, warrants, and shares under stock incentive plans. Vstock Transfer LLC will serve as the exchange agent, with the effective date to be announced at least two business days prior to implementation.
TransCode Therapeutics (NASDAQ: RNAZ) reported positive progress in its Phase 1a clinical trial of TTX-MC138, a first-in-class therapeutic targeting miR-10b for metastatic cancer treatment. Key findings include:
- 13 patients received treatment across 4 dose levels (0.8 mg/kg to 4.8 mg/kg)
- No significant safety or dose-limiting toxicities reported
- Two patients maintained stable disease for ~7 months
- 8 patients continue treatment in 28-day cycles
- PK/PD analysis shows promising results with miR-10b target engagement in 5 out of 6 analyzed patients
The positive tolerability profile and PK/PD results support advancement to the Phase 1b expansion portion of the trial.
TransCode Therapeutics (RNAZ) announced the adjournment of its Special Meeting scheduled for April 21, 2025, due to insufficient quorum, with only 12.73% of eligible shares represented. The meeting will reconvene as a virtual Adjourned Special Meeting on May 2, 2025.
The meeting aims to vote on two key proposals: Proposal One seeks approval for a reverse stock split ranging from 1:10 to 1:40 ratio, while Proposal Two addresses the potential need for further meeting adjournments. Stockholders of record as of April 2, 2025, can vote through multiple methods including mail, internet, telephone, or during the virtual meeting at www.virtualshareholdermeeting.com/RNAZ2025SM2.
TransCode Therapeutics (NASDAQ: RNAZ) has announced significant progress in its Phase 1 clinical trial of TTX-MC138, their lead therapeutic candidate designed to inhibit microRNA-10b in metastatic cancer. The first patient in Cohort 4 has received initial dosing, with two additional patients scheduled for treatment.
Key highlights include:
- Ten patients treated across four cohorts at escalating dose levels
- No significant safety or dose-limiting toxicities reported
- Seven patients remain on study for continued treatment
- Cohort 4 dosing is approximately 50% higher than Cohort 3
- Ongoing data analysis from Cohorts 1-3 shows pharmacokinetic and pharmacodynamic profiles consistent with preclinical results and Phase 0 trial
The Safety Review Committee has approved additional patient enrollment in Cohort 3 to further establish the safety profile of TTX-MC138.
TransCode Therapeutics (RNAZ) has completed a registered direct offering, raising $10 million in gross proceeds through the sale of 10,250,000 shares of common stock and accompanying warrants. The offering was priced at $0.98 per share at-the-market under Nasdaq rules, with each share accompanied by warrants to purchase additional shares.
The RNA oncology company plans to utilize the proceeds primarily for product development activities, including clinical trials of their lead therapeutic candidate TTX-MC138, IND-enabling studies, working capital, and general corporate purposes. ThinkEquity served as the sole placement agent for this offering, which was conducted under an effective shelf registration statement filed with the SEC.
TransCode Therapeutics (NASDAQ: RNAZ) has announced a registered direct offering of 10,250,000 shares of common stock and warrants at $0.98 per share. The offering includes warrants to purchase up to 10,250,000 additional shares at an exercise price of $0.86, exercisable for five years upon issuance.
The offering, expected to close on March 25, 2025, aims to raise approximately $10 million in gross proceeds. The funds will support product development activities, including clinical trials for TTX-MC138 (their lead therapeutic candidate), IND-enabling studies, working capital, and general corporate purposes. ThinkEquity serves as the exclusive placement agent for this at-the-market offering under Nasdaq rules.
TransCode Therapeutics (NASDAQ: RNAZ) has received approval from the Safety Review Committee (SRC) to proceed with Cohort 4 in its Phase I/II clinical trial for TTX-MC138, a first-in-class RNA therapeutic for metastatic cancers. The approval follows favorable safety data from Cohort 3, with no significant safety issues or dose-limiting toxicities reported across all three previous cohorts.
Key highlights:
- 6 out of 9 treated patients remain on study, with one patient receiving 7 doses over approximately 7 months
- Cohort 4 will receive a dose approximately 50% higher than Cohort 3
- SRC approved additional patient enrollment in Cohort 3
- Pharmacokinetic and pharmacodynamic data from Cohorts 1 and 2 align with preclinical and Phase 0 trial results
- Preliminary analysis suggests dose levels of 0.8-1.6 mg/kg could represent an efficacious range
TransCode Therapeutics (RNAZ), the RNA Oncology Company, announced the results of its Special Meeting held on February 25, 2025, following adjournment from February 4, 2025. Shareholders achieved a quorum and approved two key proposals:
- Proposal One: Approved the issuance of Common Stock upon exercise of Series C and D Warrants, including adjustments to warrant exercise prices, an alternative cashless exercise feature for Series D Warrants, and potential future price adjustments (subject to a $2.4882 floor price)
- Proposal Two: Approved the ability to adjourn the Special Meeting if needed for further proxy solicitation regarding the Issuance Proposal